Browse News
Filter News
Found 1,270 articles
-
Jazz Pharmaceuticals to Present Long-Term and Real-World Data Emphasizing Commitment to Treatment-Resistant Epilepsy at the 2023 American Epilepsy Society Annual Meeting
12/1/2023
Jazz Pharmaceuticals plc today announced that nine company-sponsored presentations, including five late-breaking abstracts, will be shared at the 2023 American Epilepsy Society (AES) annual meeting, being held December 1-5 in Orlando, Florida.
-
Jazz Pharmaceuticals to Present New Data Highlighting Advancements in Solid Tumors and Rare Blood Cancers at Upcoming Oncology Meetings
11/30/2023
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company and its partners will present two abstracts at the 2023 San Antonio Breast Cancer Symposium (SABCS) from December 5-9.
-
Zymeworks Announces Participation in Upcoming Investor Conference - November 30, 2023
11/30/2023
Zymeworks Inc. today announced that management will participate in an upcoming investor conference.
-
Mural Oncology Launches to Advance Pipeline of Novel Engineered Cytokine Immunotherapies
11/15/2023
Mural Oncology plc launched as an independent, publicly traded, clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation and protein engineering to develop novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers.
-
Under the potential $770.5 million deal announced Tuesday, Autifony Therapeutics is licensing to Jazz Pharmaceuticals two ion channel targets associated with neurological disorders.
-
Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
11/14/2023
Werewolf Therapeutics, Inc. provided a business update and reported financial results for the third quarter ended September 30, 2023.
-
Autifony Announces Exclusive Global License and Collaboration Agreement with Jazz Pharmaceuticals on Two Ion Channel Targets for Neurological Disorders
11/14/2023
Autifony Therapeutics Limited announced that it has entered into an exclusive global licensing agreement with Jazz Pharmaceuticals plc for up to $770.5 million to discover and develop drug candidates targeting two different ion channel targets associated with neurological disorders.
-
Narcolepsy Therapeutics Market Size to Surpass USD 6.90 Billion By 2032
11/13/2023
The global narcolepsy therapeutics market size reached USD 3.3 billion in 2022 and is projected to surpass around USD 6.90 billion by 2032, expanding at a CAGR of 7.7% from 2023 to 2032.
-
Ligand Reports Third Quarter 2023 Financial Results
11/8/2023
Ligand Pharmaceuticals Incorporated reported financial results for the three and nine months ended September 30, 2023, and provided an operating forecast and business updates.
-
Jazz Pharmaceuticals Announces Third Quarter 2023 Financial Results and Updates Financial Guidance
11/8/2023
Jazz Pharmaceuticals plc announced financial results for the third quarter of 2023 and provided business updates.
-
Jazz Pharmaceuticals and MD Anderson Announce Five-Year Collaboration to Evaluate Zanidatamab in HER2-Expressing Cancers
11/7/2023
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and The University of Texas MD Anderson Cancer Center today announced a five-year strategic research collaboration agreement to evaluate zanidatamab, Jazz's investigational HER2-targeted bispecific antibody, in multiple HER2-expressing cancers.
-
Zymeworks Provides Corporate Update and Reports Third Quarter 2023 Financial Results
11/7/2023
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel multifunctional biotherapeutics, today reported financial results for the three and nine months ended September 30, 2023 and provided a summary of recent business highlights.
-
Quest for Health Equity 2023 Summer Intern Spotlights
11/6/2023
Over the summer, the Quest for Health Equity team spearheaded a summer internship program, working with business leaders across the Quest Diagnostics organization to provide hands-on, real-work experience for scholars from the American Heart Association's Historically Black Colleges and Universities and Hispanic Serving Institutions programs.
-
Ligand Acquires Royalty on Sanofi’s TZIELD® for $20 Million
11/1/2023
Ligand Pharmaceuticals Incorporated announced that it has acquired Tolerance Therapeutics, Inc. for $20 million in cash.
-
Jazz Pharmaceuticals to Participate in Upcoming November 2023 Investor Conferences
11/1/2023
Jazz Pharmaceuticals plc announced that Company management will participate in the following upcoming investor conferences.
-
Zymeworks Announces Participation in Upcoming Investor Conferences - November 1, 2023
11/1/2023
Zymeworks Inc. today announced that management will participate in the following upcoming investor conferences.
-
Protagonist Therapeutics Announces Appointment of Daniel Swisher to Its Board of Directors
10/30/2023
Protagonist Therapeutics announced the appointment of Daniel N. Swisher, Jr. to its Board of Directors.
-
Ligand To Report Third Quarter 2023 Financial Results On November 8
10/25/2023
Ligand Pharmaceuticals Incorporated will report third quarter 2023 financial results after the close of the U.S. financial markets on Wednesday, November 8, 2023, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial results and provide a general business update.
-
Jazz Pharmaceuticals to Report 2023 Third Quarter Financial Results on November 8, 2023
10/25/2023
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2023 third quarter financial results on Wednesday, November 8, 2023, after the close of the U.S. financial markets.
-
Jazz Pharmaceuticals Presents Data Highlighting the Continued Need for Low-Sodium Treatment Option Xywav®
10/23/2023
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced new data that examine the comorbid risk of cardiovascular disease in patients with narcolepsy and idiopathic hypersomnia as well as the effect of sodium intake on cardiovascular health.